{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:14:25Z","timestamp":1767842065432,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["HO-16-18001"],"award-info":[{"award-number":["HO-16-18001"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.mayocpiqo.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T16:23:52Z","timestamp":1622046232000},"page":"596-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Estimated Public Health Impact of the Recombinant Zoster Vaccine"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5319-9493","authenticated-orcid":false,"given":"Brandon J.","family":"Patterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-3669","authenticated-orcid":false,"given":"Philip O.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-0111","authenticated-orcid":false,"given":"Desmond","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-0333","authenticated-orcid":false,"given":"Desir\u00e9e","family":"Van Oorschot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-9309","authenticated-orcid":false,"given":"Justin","family":"Carrico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8222-9914","authenticated-orcid":false,"given":"William L.","family":"Herring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6021-0582","authenticated-orcid":false,"given":"Yuanhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7232-3800","authenticated-orcid":false,"given":"Jeffrey J.","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocpiqo.2021.03.006_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2021.03.006_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4065\/84.3.274","article-title":"Herpes zoster (shingles) and postherpetic neuralgia","volume":"84","author":"Sampathkumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2021.03.006_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","article-title":"The temporal impact of aging on the burden of herpes zoster","volume":"17","author":"Varghese","year":"2017","journal-title":"BMC Geriatrics"},{"issue":"suppl 3","key":"10.1016\/j.mayocpiqo.2021.03.006_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.30","article-title":"Herpes zoster and postherpetic neuralgia","volume":"9","author":"Johnson","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2021.03.006_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11940-013-0246-5","article-title":"Complications of varicella zoster virus reactivation","volume":"15","author":"Nagel","year":"2013","journal-title":"Curr Treat Options Neurol"},{"issue":"suppl 2","key":"10.1016\/j.mayocpiqo.2021.03.006_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ophtha.2007.10.009","article-title":"Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity","volume":"115","author":"Liesegang","year":"2008","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2021.03.006_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.mayocp.2018.12.025","article-title":"Analysis of vascular event risk after herpes zoster from 2007 to 2014 US insurance claims data","volume":"94","author":"Patterson","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2021.03.006_bib9","first-page":"547","article-title":"Does herpes zoster increase the risk of stroke and myocardial infarction? A comprehensive review","volume":"8","author":"Wu","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.mayocpiqo.2021.03.006_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2021.03.006_bib11","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2021.03.006_bib12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.vaccine.2018.11.079","article-title":"Costs of herpes zoster complications in older adults: a cohort study of US claims database","volume":"37","author":"Meyers","year":"2019","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.mayocpiqo.2021.03.006_bib13","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2021.03.006_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J\u00a0Prim Prev"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2021.03.006_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/21645515.2020.1780847","article-title":"Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States","volume":"17","author":"Talbird","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2021.03.006_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"10.1016\/j.mayocpiqo.2021.03.006_bib18","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A\u00a0vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2021.03.006_bib19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2021.03.006_bib20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2021.03.006_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocpiqo.2021.03.006_bib22","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2021.03.006_bib23","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","article-title":"Assessment of the potential public health impact of herpes zoster vaccination in Germany","volume":"13","author":"Curran","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"22","key":"10.1016\/j.mayocpiqo.2021.03.006_bib24","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.vaccine.2019.04.014","article-title":"The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis","volume":"37","author":"McGirr","year":"2019","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2021.03.006_bib25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A\u00a0cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2021.03.006_bib26","doi-asserted-by":"crossref","first-page":"ofz219","DOI":"10.1093\/ofid\/ofz219","article-title":"A\u00a0cost-effectiveness analysis of an adjuvanted subunit vaccine for the prevention of herpes zoster and post-herpetic neuralgia","volume":"6","author":"Carpenter","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2021.03.006_bib27","first-page":"1567","article-title":"Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model","volume":"26","author":"Patterson","year":"2020","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2021.03.006_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2021.03.006_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.mayocp.2019.02.024","article-title":"Vaccination of adults in general medical practice","volume":"95","author":"Hunter","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2021.03.006_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.25270\/altc.2018.04.00023","article-title":"Making the Case for Universal Herpes Zoster Vaccination in Older Adults","volume":"26","author":"Famuyiro","year":"2018","journal-title":"Ann Long-Term Care"},{"key":"10.1016\/j.mayocpiqo.2021.03.006_bib34","author":"Arias"},{"key":"10.1016\/j.mayocpiqo.2021.03.006_bib35","unstructured":"United States Census Bureau. Annual estimates of resident population by single year of age and sex for the United States. April 1, 2010 to July 1, 2015. American Fact Finder. Generated interactively. https:\/\/data.census.gov\/, Accessed 2017 February 6."},{"issue":"4","key":"10.1016\/j.mayocpiqo.2021.03.006_bib36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/21645515.2018.1558689","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live","volume":"15","author":"Curran","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.mayocpiqo.2021.03.006_bib37","unstructured":"United States Census Bureau. Annual estimates of resident population by single year of age and sex for the United States. April 1, 2010 to July 1, 2015. American Fact Finder. Generated interactively. https:\/\/data.census.gov\/, Accessed 2017 February 6"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2021.03.006_bib38","doi-asserted-by":"crossref","first-page":"e10180","DOI":"10.2196\/10180","article-title":"monitoring interest in herpes zoster vaccination: analysis of Google search data","volume":"4","author":"Berlinberg","year":"2018","journal-title":"JMIR Public Health Surveill"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2021.03.006_bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.7326\/0003-4819-152-9-201005040-00005","article-title":"Barriers to the use of herpes zoster vaccine","volume":"152","author":"Hurley","year":"2010","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2021.03.006_bib40","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/03007995.2017.1416347","article-title":"Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis","volume":"34","author":"Yan","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2021.03.006_bib41","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.vaccine.2019.01.044","article-title":"A\u00a0pathway to developing and testing quality measures aimed at improving adult vaccination rates in the United States","volume":"37","author":"Shen","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2021.03.006_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2021.03.006_bib43","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2013.06.046","article-title":"From the Medical Board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis","volume":"69","author":"Wine-Lee","year":"2013","journal-title":"J\u00a0Am Acad Dermat"},{"issue":"43","key":"10.1016\/j.mayocpiqo.2021.03.006_bib44","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1016\/j.vaccine.2014.08.040","article-title":"Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies","volume":"32","author":"Teeter","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2021.03.006_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amepre.2003.09.020","article-title":"Physician and practice factors related to influenza vaccination among the elderly","volume":"26","author":"Zimmerman","year":"2004","journal-title":"Am J Prev Med"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2021.03.006_bib46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1370\/afm.1542","article-title":"Vaccinations administered during off-clinic hours at a national community pharmacy: implications for increasing patient access and convenience","volume":"11","author":"Goad","year":"2013","journal-title":"Ann Fam Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2021.03.006_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/003335491412900203","article-title":"Recommendations from the National Vaccine Advisory Committee: standards for adult immunization practice","volume":"129","year":"2014","journal-title":"Public Health Rep"},{"key":"10.1016\/j.mayocpiqo.2021.03.006_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (shingrix) real-world effectiveness in the first two years post-licensure","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mayocpiqo.2021.03.006_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab121","article-title":"Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study","author":"Sun","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454821000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454821000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:09:53Z","timestamp":1762870193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454821000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2542454821000539"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2021.03.006","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimated Public Health Impact of the Recombinant Zoster Vaccine","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}